The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 35 | — | 20.1x | Near average | |
Growth | 67 | — | 5.6% | Near average | |
Quality | 69 | 347.3% | 7.6% | Above average | |
Safety | 22 | 4.5x | 0.4x | Below average | |
Capital Return | 30 | — | 2.19% | Below average | |
Momentum | 95 | — | — | Above average | |
Sentiment | 56 | — | — | Near average |
Verona Pharma plc is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Verona Pharma plc shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Verona Pharma stock has experienced a notable negative shift in analyst sentiment, with the stock being downgraded by five major financial institutions (such as Jefferies and Wells Fargo) from 'Buy' ratings to 'Neutral' or 'Hold'. Despite the average price target stabilizing at 75.73 dollars, the current market price (106.91 dollars) significantly exceeds this average, suggesting that analysts view the stock as currently overvalued.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.